ArticleBlood advances2020

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.

Kitsada Wudhikarn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.